

Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

Kane Biotech Announces Third Quarter 2020 Financial Results

Nov 26 2020, 5:30 PM EST

Kane Biotech to Release Third Quarter 2020 Financial Results on November 26 – Conference Call to Follow

Nov 19 2020, 5:30 PM EST

Kane Biotech Enters into Credit Facility with Pivot Financial

Nov 5 2020, 5:00 PM EST

Stock Overview

Symbol	KNE
Exchange	TSXV
Market Cap	16.84m
Last Price	\$0.155
52-Week	\$0.09 - \$0.26

11/27/2020 02:53 PM EST

Investor Relations

Harbor Access LLC
Graham Farrell
Managing Partner
130 King St. W
Suite 1900
Toronto, ON
T: (416) 842 9003
graham.farrell@harboraccessllc.com

Board of Directors

Mr. Philip Renaud

Chairman

Mr. Mark Nawacki

Director

Marc Edwards

Director, Interim Chief Executive Officer

Rashieda Gluck

Director

Kane Biotech Inc.

162-196 Innovation Drive
Winnipeg, Manitoba R3T 2N2
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.